Trial Profile
An Open Label, Phase 2 Study of the Safety and Antiretroviral Activity of 3BNC117 in HIV-Infected Individuals on Combination Antiretroviral Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Teropavimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 11 Mar 2020 Results (n=19) presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 14 Nov 2018 New trial record